Research blog
Peptide research guides without hype.
Browse source-first articles on research basics, COA reading, clinical-trial terms, comparison pages, and peptide claim boundaries.
Educational disclaimer: Articles are for research literacy only. No medical advice, dosing, protocols, sourcing instructions, or recommendations to buy or use any compound.
Tesamorelin and AOD-9604: Source Check for Research Readers
A source-first guide to tesamorelin label and trial evidence versus the thinner public evidence trail for AOD-9604.
Read article →Research brief • 2026-06-13CJC-1295 and Ipamorelin: Research Literacy Check
A source-first guide to separating CJC-1295 GHRH-analog research from ipamorelin ghrelin-mimetic claims.
Read article →Research brief • 2026-06-12BPC-157 and Sermorelin: Source Check for Research Readers
A source-first guide to separating BPC-157 translational evidence from sermorelin/GHRH analog trial context.
Read article →Research brief • 2026-06-12BPC-157 and Sermorelin: Research Literacy Check
A source-first guide to separating BPC-157 repair-peptide claims from sermorelin growth-hormone-axis research.
Read article →Research brief • 2026-06-11Retatrutide “GLP-3” and MOTS-c: Registry vs Mechanism Check
A source-first guide to separating retatrutide trial registry evidence, online GLP-3 shorthand, and MOTS-c mechanism claims.
Read article →Research brief • 2026-06-11Tirzepatide and MOTS-c: Research Literacy Check
A source-first guide to separating tirzepatide clinical-trial evidence from MOTS-c mitochondrial mechanism claims.
Read article →Research brief • 2026-06-11Retatrutide “GLP-3” and MOTS-c: Source Check for Research Readers
A source-first guide to separating retatrutide triple-agonist clinical records from MOTS-c mitochondrial mechanism claims and online GLP-3 shorthand.
Read article →Research brief • 2026-06-10Retatrutide, Semaglutide, and MOTS-c: Research Check
A source-first comparison of retatrutide triple-agonist evidence, semaglutide GLP-1 context, and MOTS-c mechanism claims.
Read article →Research brief • 2026-06-10Retatrutide, “GLP-3,” and MOTS-c: Source Ladder for Research Readers
A source-first guide to separating retatrutide triple-agonist trial records from MOTS-c mitochondrial mechanism claims and online GLP-3 shorthand.
Read article →Research brief • 2026-06-09TB-500 and GHK-Cu: Repair-Peptide Hype Check
A source-first brief on TB-500/thymosin beta-4 and GHK-Cu copper peptide research, evidence levels, and claim boundaries.
Read article →Research brief • 2026-06-09TB-500 and GHK-Cu: Research Literacy Check for 2026
A source-first review of TB-500/thymosin beta-4 and GHK-Cu copper peptide claims, evidence boundaries, and research-reading guardrails.
Read article →Research brief • 2026-06-09Retatrutide (GLP-3) and MOTS-c: Metabolic Research Review 2026
A June 9, 2026 metabolic research update comparing retatrutide triple-agonist mechanism data with MOTS-c mitochondrial signaling studies.
Read article →Research brief • 2026-06-08NAD+ and LL-37: Source Check for Research Readers
A source-first guide to NAD+ metabolism searches, LL-37 host-defense peptide research, and evidence-boundary reading.
Read article →Research brief • 2026-06-08Retatrutide “GLP-3” and MOTS-c: Metabolic Research Source Check
A source-first guide comparing retatrutide triple-agonist clinical evidence with MOTS-c mitochondrial-derived peptide research.
Read article →Research brief • 2026-06-07Retatrutide “GLP-3” and MOTS-c: Source Check for June 2026
A source-first guide to separating retatrutide triple-agonist clinical evidence from MOTS-c mitochondrial-derived peptide claims.
Read article →Research brief • 2026-06-06Tesamorelin and Ipamorelin: Research Literacy Check
A source-first guide to tesamorelin label context, ipamorelin ghrelin-mimetic research, and evidence-quality boundaries.
Read article →Research brief • 2026-06-05Retatrutide “GLP-3” and MOTS-c: Source Check for Research Readers
A source-first guide to separating retatrutide triple-agonist clinical evidence, the online GLP-3 nickname, and MOTS-c mitochondrial mechanism claims.
Read article →Research brief • 2026-06-03Semaglutide and GHK-Cu: Research Literacy Check
A source-first guide to separating semaglutide GLP-1 clinical/regulatory context from GHK-Cu copper-peptide mechanism research.
Read article →Research brief • 2026-06-02BPC-157 and Retatrutide: Evidence-Over-Hype Research Watch
A source-first guide to separating BPC-157 mechanism-heavy claims from retatrutide GLP-1/GIP/glucagon human-trial context.
Read article →Research brief • 2026-06-01Tirzepatide and Tesamorelin: Research Check for June 2026
A source-first guide to separating tirzepatide GLP-1/GIP trial evidence from tesamorelin's narrower HIV-associated lipodystrophy context.
Read article →Research brief • 2026-05-26Retatrutide “GLP-3” + MOTS-c: Evidence Check for Research Readers
A source-first guide to separating retatrutide human-trial records from MOTS-c mechanism-first claims and social-media shorthand.
Read article →Research brief • 2026-05-25Retatrutide “GLP-3” + MOTS-c: Claim-Check Notes for 2026
A fresh claim-check guide for separating retatrutide human-trial evidence, GLP-3 shorthand, MOTS-c mechanism claims, and active trial listings.
Read article →Research brief • 2026-05-24Retatrutide “GLP-3” + MOTS-c: A Source Ladder for Trend Claims
A source-ladder guide for checking retatrutide human-trial claims, GLP-3 shorthand, and MOTS-c mechanism-first content without hype.
Read article →Research brief • 2026-05-23Retatrutide “GLP-3” + MOTS-c: Trial Signals vs Mechanism Claims
A source-first guide to separating retatrutide human-trial evidence from MOTS-c mechanism-first claims and social-media shorthand.
Read article →Research brief • 2026-05-22Retatrutide “GLP-3” and MOTS-c Evidence Ladder
A source-first guide to reading retatrutide, the online GLP-3 nickname, and MOTS-c claims through PubMed, ClinicalTrials.gov, and evidence levels.
Read article →Research guide • 2026-05-18What Does Research Use Only Mean?
A plain-English guide to research use only language, what it does and does not mean, and how to avoid turning labels into safety claims.
Read article →Research guide • May 20, 2026How to Read a Peptide Study
A beginner guide to reading peptide studies by checking study type, endpoints, methods, limitations, and claim boundaries.
Read article →Research guide • May 20, 2026Animal vs Human Peptide Research
How to compare animal peptide research with human clinical evidence without overstating early or indirect findings.
Read article →Research guide • May 20, 2026Peptide Evidence Levels Explained
A practical framework for ranking peptide claims from marketing copy to preclinical evidence, human trials, and regulatory documents.
Read article →Research guide • May 20, 2026How to Check Peptide Claims on PubMed
Use PubMed to verify peptide claims by searching names, checking abstracts, reading study type, and avoiding overconfident conclusions.
Read article →Research guide • May 20, 2026Peptide COA Basics
COA basics for peptide research readers: lot numbers, purity, identity testing, dates, lab details, and common red flags.
Read article →Research guide • May 20, 2026HPLC vs LC-MS Peptide Testing
HPLC vs LC-MS peptide testing explained for research readers: what each method can show, what it cannot prove, and how to read COAs carefully.
Read article →Research guide • 2026-05-18PubMed Peptide Research Guide
How to use PubMed for peptide research without over-reading abstracts, old papers, or mechanism-only evidence.
Read article →Research guide • 2026-05-19ClinicalTrials.gov Peptide Research Guide
Use ClinicalTrials.gov for peptide research: search terms, trial phases, recruitment status, endpoints, and result limits.
Read article →Research guide • 2026-05-19Affiliate Disclosures in Peptide Content
Affiliate disclosures in peptide research content explained: why transparency matters and how to read monetized recommendations.
Read article →Research guide • 2026-05-18BPC-157 Research Overview
An education-first BPC-157 research overview focused on study types, mechanisms discussed in literature, and claim boundaries.
Read article →Research guide • 2026-05-19Cagrilintide Research Basics
Cagrilintide research basics: amylin analog terminology, metabolic endpoints, combination-study context, and evidence limits.
Read article →Research guide • 2026-05-19Peptide Supplier Transparency Checklist
Check peptide supplier transparency without buying hype: documentation, testing, disclosures, claim language, and red flags.
Read article →Research guide • 2026-05-19Compare Metabolic Peptide Studies Without Hype
Compare metabolic peptide studies without hype by checking study design, endpoints, duration, population, and claim boundaries.
Read article →Research guide • 2026-05-19Epitalon Research Claims Checked
Epitalon research and telomere claims checked: aging-biology terminology, evidence limits, and cautious interpretation.
Read article →Research guide • 2026-05-19FDA Approval vs Research Use for Peptides
FDA approval vs research use explained for peptide topics: claim boundaries, approved contexts, and cautious language.
Read article →Research guide • 2026-05-17GHK-Cu Copper Peptide Research Overview
GHK-Cu, also called glycyl-histidyl-lysine copper, is a naturally occurring copper-binding peptide complex studied in relation to skin biology, tissue remodeling, inflammation pathways, oxidative stress, and aging-related research questions.
Read article →Research guide • 2026-05-18GHK-Cu Research Overview
An SEO-friendly GHK-Cu research overview covering copper peptide terminology, skin biology, tissue remodeling, and cautious evidence interpretation.
Read article →Research guide • 2026-05-18GLP-1, GIP, and Glucagon Receptors
Beginner-friendly explanation of GLP-1, GIP, and glucagon receptor terminology in metabolic peptide research.
Read article →Research guide • 2026-05-19GLP-1 vs GIP Receptors Explained
GLP-1 vs GIP receptors explained for research readers: receptor roles, study endpoints, evidence limits, and cautious claim checks.
Read article →Research guide • 2026-05-19Glucagon Receptor Research Basics
A beginner-safe glucagon receptor research guide covering metabolic signaling, trial endpoints, and evidence boundaries.
Read article →Research guide • 2026-05-18How to Read a Peptide COA
How to read a peptide certificate of analysis by checking lot numbers, purity, methods, dates, lab identity, and claim boundaries.
Read article →Research guide • 2026-05-18How to Read a Peptide Study Abstract
A beginner guide to reading peptide study abstracts by checking population, model, endpoints, methods, and claim boundaries.
Read article →Research guide • 2026-05-18How to Spot Exaggerated Peptide Claims
A claim-checking guide for spotting exaggerated peptide marketing, outcome promises, missing evidence, and source-document mismatches.
Read article →Research guide • 2026-05-19Incretin Research Endpoints Explained
Incretin research endpoints explained for beginners: A1C, weight-change, safety reporting, dropout rates, and trial limits.
Read article →Research guide • 2026-05-19LL-37 Peptide Research Terms Explained
LL-37 peptide research explained: host-defense terminology, antimicrobial peptide context, and cautious evidence interpretation.
Read article →Research guide • 2026-05-19MOTS-c Research: Mitochondrial Peptide Basics
MOTS-c research basics: mitochondrial-derived peptide terminology, mechanism signals, human-study limits, and source checks.
Read article →Research guide • 2026-05-19NAD+ Peptide-Adjacent Research Searches
NAD+ peptide-adjacent research searches explained: metabolism terminology, aging-biology context, and careful source reading.
Read article →Research guide • 2026-05-07Not every “fat-loss peptide” is the same
TikTok often puts tesamorelin, AOD-9604, and GLP-1 related peptides into one giant fat-loss bucket. Researchers do not treat them that way. Mechanism, evidence quality, medical context, and claim language all matter.
Read article →Research guide • 2026-05-19Orforglipron Research Basics
Orforglipron research explained as an oral GLP-1 study topic: mechanisms, endpoints, and cautious evidence interpretation.
Read article →Research guide • 2026-05-18Peptide Clinical Trials Explained
How peptide clinical trials are structured, what phases mean, and why trial evidence differs from online research-use claims.
Read article →Research guide • 2026-05-19Peptide COA Methods: HPLC vs LC-MS
HPLC vs LC-MS on peptide COAs: what the methods usually indicate, what they miss, and how to read claims cautiously.
Read article →Research guide • 2026-05-18Peptide COA Red Flags
Common peptide COA red flags: missing lot numbers, unclear lab identity, old dates, weak methods, and mismatched supplier claims.
Read article →Research guide • 2026-05-18Peptide Half-Life Explained
A plain-English explanation of peptide half-life, why researchers discuss it, and why it is not dosing guidance.
Read article →Research guide • 2026-05-19Peptide Identity Testing Explained
Peptide identity testing explained for research readers: why identity and purity are different checks with different limits.
Read article →Research guide • 2026-05-19Peptide Impurities and Unknown COA Peaks
Unknown peaks on peptide COAs explained: what chromatograms may show, what remains uncertain, and which claims need caution.
Read article →Research guide • 2026-05-19Peptide Lot Numbers on COAs
Peptide lot numbers on COAs explained: match reports to products, dates, methods, and supplier claims before trusting a document.
Read article →Research guide • 2026-05-18Peptide Mechanism of Action Explained
What mechanism of action means in peptide research and why mechanism is not the same as proven outcomes.
Read article →Research guide • 2026-05-19Peptide Purity Percentages Explained
What does 99% peptide purity mean? Learn how purity percentages are reported and why they do not prove safety or use.
Read article →Research guide • 2026-05-18Peptide Purity Testing Explained
Peptide purity testing explained in plain English: what purity can show, what it cannot prove, and how to compare supplier claims.
Read article →Research guide • 2026-05-18Peptide Purity vs Identity Testing
The difference between peptide purity testing and identity testing, and why both are narrower than broad quality or safety claims.
Read article →Research guide • 2026-05-18Peptide Research and FDA Status
How to think about peptide research, FDA approval status, research-use labeling, and why online claims need careful separation.
Read article →Research guide • 2026-05-19Peptide Study Design: RCT vs Open-Label Studies
Peptide study design explained: randomized, open-label, observational, placebo-controlled, and why design affects conclusions.
Read article →Research guide • 2026-05-19Peptide Study Endpoints: Biomarkers vs Symptoms
Peptide study endpoints explained: biomarkers, symptoms, surrogate measures, clinical outcomes, and cautious interpretation.
Read article →Research guide • 2026-05-18Peptide Supplier Checklist
A neutral peptide supplier checklist for reviewing COAs, posted testing, claim language, affiliate disclosures, and transparency signals.
Read article →Research guide • 2026-05-19Peptide Supplier Red Flags: Claims and Testing
Peptide supplier red flags: vague testing, missing disclosures, aggressive claims, unclear COAs, and hype-heavy language.
Read article →Research guide • 2026-05-19Preclinical vs Human Peptide Evidence
Preclinical peptide research vs human clinical evidence: how to compare model studies, endpoints, and claim strength safely.
Read article →Research guide • 2026-05-19Read Peptide Marketing Claims Like a Researcher
Read peptide marketing claims like a researcher by checking evidence level, endpoints, wording, citations, and missing context.
Read article →Research guide • 2026-05-05Retatrutide 2026 Research Update
Retatrutide, also known as LY3437943, is one of the most watched next-generation incretin research compounds because it is designed to activate three hormone-receptor pathways: GIP, GLP-1, and glucagon. Here is the education-first update without dosage advice, protocols, or hype.
Read article →Research guide • 2026-05-14Retatrutide GLP-3 and MOTS-c Evidence Map
Today\u2019s video topic paired retatrutide, often nicknamed \u201cGLP-3\u201d online, with MOTS-c. Both are discussed in peptide communities, but the evidence base behind each topic is very different. Retatrutide sits in a clinical-trial pipeline. MOTS-c remains more mechanism-first, with a smaller human-trial fo
Read article →Research guide • May 20, 2026Retatrutide “GLP-3” and MOTS-c: what today’s source check actually supports
A research-literacy update on retatrutide, the online GLP-3 nickname, and MOTS-c. Learn how to separate clinical evidence, mechanism papers, and trend claims.
Read article →Research guide • 2026-05-17Retatrutide GLP-3 and MOTS-c Evidence Check
Today\u2019s Peptide Daily Report video topic paired retatrutide, often nicknamed \u201cGLP-3\u201d online, with MOTS-c. Both are high-interest peptide research topics, but they sit in very different evidence categories: retatrutide has a growing clinical-trial record, while MOTS-c is still mostly a mechanism-firs
Read article →Research guide • 2026-05-13Retatrutide GLP-3 and MOTS-c Research Brief
Retatrutide and MOTS-c are both showing up in peptide conversations, but they represent two very different evidence stories. Retatrutide is an investigational triple-receptor agonist moving through human clinical trials. MOTS-c is a mitochondrial-derived peptide studied mainly through mechanism, cel
Read article →Research guide • 2026-05-08Retatrutide and MOTS-c Evidence Differences
Retatrutide is often nicknamed \u201cGLP-3\u201d online because it is designed to activate three incretin-related receptor pathways. MOTS-c is a mitochondrial-derived peptide discussed in cellular metabolism research. They are both trending, but the evidence behind them is not the same.
Read article →Research guide • 2026-05-19Retatrutide “GLP-3” and MOTS-c: a source-check for two trending peptide claims
An education-first source-check of retatrutide, often nicknamed GLP-3 online, and MOTS-c. Learn how trial-stage evidence differs from mechanism-based peptide claims.
Read article →Research guide • 2026-05-18Retatrutide GLP-3 vs MOTS-c Evidence Types
Today\u2019s video topic keeps returning to the same research-literacy problem: retatrutide, nicknamed \u201cGLP-3\u201d online, and MOTS-c are both popular peptide topics, but they are not supported by the same kind of evidence. Retatrutide is moving through a large clinical-development pipeline. MOTS-c remains a
Read article →Research guide • 2026-05-19Retatrutide vs tirzepatide: research comparison, evidence limits, and claim checks
Retatrutide vs tirzepatide research comparison: receptor targets, trial stages, endpoints, evidence limits, and cautious claim checks.
Read article →Research guide • 2026-05-19Selank Research Claims and Evidence Limits
Selank research literacy guide: neurobiology claims, evidence limits, source checks, and cautious language for beginners.
Read article →Research guide • 2026-05-18Semaglutide vs Tirzepatide vs Retatrutide
A research-literacy comparison of semaglutide, tirzepatide, and retatrutide by receptor targets, evidence maturity, and claim boundaries.
Read article →Research guide • 2026-05-19Semax Research Claims Checked
Semax research and neurobiology study claims checked: source types, evidence limits, and cautious interpretation.
Read article →Research guide • 2026-05-19Survodutide Research: GLP-1 and Glucagon Basics
Survodutide research literacy guide: GLP-1/glucagon dual agonist terminology, endpoints, and careful source checking.
Read article →Research guide • 2026-05-18TB-500 Research Overview
A research-literacy overview of TB-500 and thymosin beta-4 discussions, including actin, cell migration, tissue remodeling, and evidence boundaries.
Read article →Research guide • 2026-05-19Third-Party Peptide Lab Reports Checklist
Third-party peptide lab reports explained: lab identity, methods, dates, lot matching, and claim boundaries to verify.
Read article →Research guide • 2026-05-18Third-Party Testing vs In-House Testing
How to compare third-party peptide testing claims with in-house reports while staying cautious about what testing proves.
Read article →Research guide • 2026-05-19Thymosin Alpha-1 Research Basics
Thymosin alpha-1 research basics: immune signaling terminology, study contexts, evidence limits, and claim boundaries.
Read article →Research guide • 2026-05-19Triple Agonist Peptide Research Explained
Triple agonist peptide research explained: GLP-1, GIP, and glucagon receptor logic, endpoints, and hype-checking basics.
Read article →Research guide • 2026-05-18What Is a GLP-1 Receptor Agonist?
A beginner-friendly explanation of GLP-1 receptor agonists, metabolic research endpoints, approved contexts, and careful claim boundaries.
Read article →